• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

GRAS Notices

  • Print
  • Share
  • E-mail

GRN No. 660

Substance: Bacillus coagulans GBI-30, 6086 spores
Intended Use: Intended for use as an ingredient in non-exempt term infant formula at levels up to 2 x 108 CFUs per 100 mL of infant formula as consumed.
Basis: Scientific procedures
Notifier: Ganeden Biotech, Inc.
5800 Landerbrook Drive, Suite 300; Mayfield Heights, Ohio 44124
Date of filing: Aug 16, 2016
GRAS Notice (releasable information): GRN 660 (in PDF) (3.6 MB)
Date of closure: Jan 13, 2017
FDA's Letter: FDA has no questions (in PDF) (81 kB)
Notes: Infant formula uses. Same strain at GRN 399, though not a spore, and for use in infant formula (not covered in GRN 399)